4.7 Review

Harnessing multimodal data integration to advance precision oncology

Journal

NATURE REVIEWS CANCER
Volume 22, Issue 2, Pages 114-126

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41568-021-00408-3

Keywords

-

Categories

Funding

  1. Nicholls-Biondi Endowed Chair in Computational Oncology
  2. Susan G. Komen Scholars programme
  3. National Cancer Institute (NCI) of the US National Institutes of Health (NIH) [F30CA257414]
  4. Jonathan Grayer Fellowship of Gerstner Sloan Kettering Graduate School of Biomedical Sciences
  5. Medical Scientist Training Program Grant from the National Institute of General Medical Sciences of the NIH [T32GM007739]
  6. Cycle for Survival
  7. NIH NCI Cancer Center Support Grant [P30 CA008748]

Ask authors/readers for more resources

Advancements in quantitative biomarker development have accelerated insights for cancer patients, but integrated approaches across modalities remain underdeveloped. To succeed, efforts in data engineering, computational methods for heterogeneous data analysis, and instantiation of synergistic data models in biomedical research are necessary.
Advances in quantitative biomarker development have accelerated new forms of data-driven insights for patients with cancer. However, most approaches are limited to a single mode of data, leaving integrated approaches across modalities relatively underdeveloped. Multimodal integration of advanced molecular diagnostics, radiological and histological imaging, and codified clinical data presents opportunities to advance precision oncology beyond genomics and standard moleculartechniques. However, most medical datasets are still too sparse to be useful for the training of modern machine learning techniques, and significant challenges remain before this is remedied. Combined efforts of data engineering, computational methods for analysis of heterogeneous data and instantiation of synergistic data models in biomedical research are required for success. In this Perspective, we offer our opinions on synthesizing complementary modalities of data with emerging multimodal artificial intelligence methods. Advancing along this direction will result in a reimagined class of multimodal biomarkers to propel the field of precision oncology in the coming decade.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available